Eligible SPK candidates are defined as diabetic patients on insulin treatment with a C-peptide ≤ 2 ng/mL, or C-peptide ≥ 2 ng/mL and BMI < 28 kg/m2, to permit and define eligibility for type 2 diabetes candidates. This evidence concerns the gene INS and type 2 diabetes mellitus.